Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Paksusuolissa toimitetun B2-vitamiinin vaikutus suoliston mikrobiotaan ja siihen liittyviin terveysbiomarkkereihin terveillä iäkkäillä aikuisilla

perjantai 6. marraskuuta 2026 päivittänyt: dsm-firmenich Switzerland AG

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Tutkimuksen yleiskatsaus

Tila

Valmis

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

348

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Cork, Irlanti
        • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

50 vuotta - 70 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a BMI of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the investigational product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.

  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)

  3. Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.

  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).

  5. Is a smoker or vaper.

  6. Vegetarian or vegan.

  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).

  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.

  9. Has a currently active eating disorder.

  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.

  11. Is having a typical fibre intake >30 g fibre/day.

  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.

  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.

  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.

  15. Has a current or history of any gastrointestinal cancer

  16. Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).

  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).

  18. Have a current malignant disease or any concomitant end-stage organ disease.

  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.

  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).

  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Low dose

Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Kokeellinen: Mid dose

Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Kokeellinen: high dose

Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Placebo Comparator: Placebo

One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

Colon delivered vitamin B2 (Riboflavin) for 12 weeks

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Faecal microbial composition
Aikaikkuna: from baseline to 12 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

from baseline to 12 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Alpha diversity
Aikaikkuna: from baseline to 12 weeks

Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

from baseline to 12 weeks
Beta diversity
Aikaikkuna: week 0 to week 12

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

week 0 to week 12
Faecal microbial metabolites fatty acid content at baseline and week 12
Aikaikkuna: from baseline to 12 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

from baseline to 12 weeks
Acetate, Propionate and Butyrate
Aikaikkuna: baseline and week 12

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

baseline and week 12
Intestinal inflammation
Aikaikkuna: from baseline to 12 weeks

Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

from baseline to 12 weeks
Intestinal barrier integrity
Aikaikkuna: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Oxidative stress in blood
Aikaikkuna: from baseline to 12 weeks

Oxidative stress level measured as free thiol content in blood at baseline and at week 12

from baseline to 12 weeks
Inflammatory status in blood
Aikaikkuna: from baseline to 12 weeks

Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

from baseline to 12 weeks
Gastrointestinal symptoms
Aikaikkuna: from baseline to 12 weeks

Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

from baseline to 12 weeks
health-related quality of life
Aikaikkuna: from baseline to 12 weeks

Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12.

The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

from baseline to 12 weeks
Stool consistency
Aikaikkuna: from baseline to 12 weeks

Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12).

Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

from baseline to 12 weeks
Stool frequency
Aikaikkuna: from baseline to 12 weeks

Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

from baseline to 12 weeks
Systemic vitamin status
Aikaikkuna: from baseline to 12 weeks

The concentration of B vitamins in blood at baseline

from baseline to 12 weeks
Faecal physiological pH and redox
Aikaikkuna: from baseline to 12 weeks

Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

from baseline to 12 weeks
Faecal microbial composition at week 4
Aikaikkuna: from baseline to 4 weeks

Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

from baseline to 4 weeks
Alpha diversity at week 4
Aikaikkuna: baseline to Week 4.

Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

baseline to Week 4.
Beta diversity at week 4
Aikaikkuna: week 0 to week 4

Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

week 0 to week 4
Microbial metabolites at week 4
Aikaikkuna: from baseline to 4 weeks

Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

from baseline to 4 weeks
Acetate, Propionate and Butyrate at week 4
Aikaikkuna: week 0 to week 4

Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

week 0 to week 4

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Skin barrier integrity
Aikaikkuna: from baseline to 12 weeks

Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

from baseline to 12 weeks
Skin hydration
Aikaikkuna: from baseline to 12 weeks

Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

from baseline to 12 weeks
Objective skin-health
Aikaikkuna: from baseline to 12 weeks

Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

from baseline to 12 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Prof Timothy Dinan, Cork University Hospital

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 12. joulukuuta 2022

Ensisijainen valmistuminen (Todellinen)

Torstai 6. heinäkuuta 2023

Opintojen valmistuminen (Todellinen)

Torstai 6. heinäkuuta 2023

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 16. helmikuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 27. maaliskuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Perjantai 7. huhtikuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 10. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 6. marraskuuta 2026

Viimeksi vahvistettu

Perjantai 1. syyskuuta 2023

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa